HAEMONETICS CORP (HAE) FY2025 10-K Annual Report
HAEMONETICS CORP (HAE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 21, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
HAEMONETICS CORP FY2025 10-K Analysis
Business Overview
- • Core business: Medical devices and technologies for plasma collection, blood centers, and hospitals
- • Emphasis on Plasma and Hospital segments as primary growth drivers; Blood Center focused on targeted plasma and platelet opportunities
Management Discussion & Analysis
- • Revenue $1.361B, up 4.0% YoY; Hospital segment up 23.7% ($564M vs $456M), Plasma down 6.0% ($535M vs $570M), Blood Center down 7.8% ($261M vs $283M)
- • Operating margin 16.3% vs 12.6%; gross margin 55.0% vs 52.8%; net income margin 12.3% vs 9.0%
Risk Factors
- • Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
- • Share repurchase program could increase stock price volatility and reduce market liquidity for common stock
HAEMONETICS CORP FY2025 Key Financial MetricsXBRL
Revenue
$1.4B
▲ +4.0% YoY
Net Income
$168M
▲ +42.6% YoY
Gross Margin
55.0%
▲ +221bp YoY
Operating Margin
16.3%
▲ +370bp YoY
Net Margin
12.3%
▲ +334bp YoY
ROE
20.4%
▲ +818bp YoY
Total Assets
$2.5B
▲ +11.6% YoY
EPS (Diluted)
$3.31
▲ +44.5% YoY
Operating Cash Flow
$182M
▼ -0.0% YoY
Source: XBRL data from HAEMONETICS CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on HAEMONETICS CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.